Highland Capital Management LLC Has $976,000 Stake in Fresenius Medical Care AG (NYSE:FMS)

Highland Capital Management LLC cut its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,100 shares of the company’s stock after selling 1,100 shares during the quarter. Highland Capital Management LLC’s holdings in Fresenius Medical Care were worth $976,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Creative Planning grew its holdings in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after acquiring an additional 6,373 shares during the period. Verition Fund Management LLC bought a new stake in shares of Fresenius Medical Care during the 3rd quarter valued at about $237,000. Charles Schwab Investment Management Inc. grew its stake in Fresenius Medical Care by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after purchasing an additional 2,233 shares during the period. Quantinno Capital Management LP increased its holdings in Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Finally, MML Investors Services LLC increased its holdings in Fresenius Medical Care by 5.3% in the third quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after purchasing an additional 753 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on FMS shares. Truist Financial raised their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price target for the company. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Friday, January 3rd. They set a “strong-buy” rating on the stock. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.

Fresenius Medical Care Stock Performance

NYSE FMS opened at $24.95 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a fifty day simple moving average of $23.09 and a 200 day simple moving average of $21.15. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $25.17. The company has a market cap of $14.64 billion, a P/E ratio of 20.62, a PEG ratio of 0.75 and a beta of 0.92.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.36 billion. During the same quarter in the prior year, the business posted $0.31 EPS. Sell-side analysts predict that Fresenius Medical Care AG will post 1.53 earnings per share for the current fiscal year.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.